First Breath-Actuated, Dry-Powder Inhaler for Acute Asthma Approved – Monthly Prescribing Reference


Monthly Prescribing Reference

First Breath-Actuated, Dry-Powder Inhaler for Acute Asthma Approved
Monthly Prescribing Reference
Teva announced that the Food and Drug Administration (FDA) has approved ProAir RespiClick (albuterol sulfate inhalation powder), the first breath-actuated dry-powder inhaler approved for acute asthma symptoms. ProAir RespiClick is indicated for the …
FDA clears Teva asthma med (TEVA)Seeking Alpha (registration)
FDA Approves Teva's New Asthma TreatmentArutz Sheva
FDA approves ProAir RespiClick for treatment of acute asthma symptomsHealio
PharmiWeb.com (press release)
all 10 news articles »

View full post on asthma – Google News

Treatment of acute asthma among pregnant women improves over 17-year period – Healio

Treatment of acute asthma among pregnant women improves over 17-year period
Healio
“On the basis of four observational studies of pregnant women with acute asthma in 48 EDs, we found a significant increase in the ED administration of systemic corticosteroids and prescription of systemic corticosteroids at ED discharge over the 17

and more »

View full post on asthma – Google News

Improved Management of Acute Asthma among Pregnant Women Presenting to the Emergency Department.

Related Articles

Improved Management of Acute Asthma among Pregnant Women Presenting to the Emergency Department.

Chest. 2014 Oct 30;

Authors: Hasegawa K, Cydulka RK, Sullivan AF, Langdorf MI, Nonas SA, Nowak RM, Wang NE, Camargo CA

Abstract
Abstract: Background:A multicenter study in the late 1990s demonstrated suboptimal emergency asthma care for pregnant women in US emergency departments (EDs). After a decade, follow-up data are lacking. We aimed to examine changes in emergency asthma care of pregnant women since the 1990s. Methods:We combined data from four multicenter observational studies of ED patients with acute asthma performed in 1996-2001 (three studies), and 2011-2012 (one study). We restricted the data so that comparisons were based on the same 48 EDs in both time periods. We identified all pregnant patients aged 18 to 44 years with acute asthma. Primary outcomes were treatment with systemic corticosteroids in the ED, and, among those sent home, at ED discharge. Results:Of 4895 ED patients with acute asthma, the analytic cohort comprised 125 pregnant women. Over the two time periods, there were no significant changes in patient demographics, chronic asthma severity, or initial peak expiratory flow. In contrast, ED systemic corticosteroids treatment increased significantly from 51% to 78% across the time periods (OR 3.11; 95%CI 1.27-7.60; P=0.01); systemic corticosteroids at discharge increased from 42% to 63% (OR 2.49; 95%CI 0.97-6.37; P=0.054). In the adjusted analyses, pregnant women in recent years were more likely to receive systemic corticosteroids, both in ED (OR 4.76; 95%CI 1.63-13.9; P=0.004) and at discharge (OR 3.18; 95%CI 1.05-9.61; P=0.04). Conclusions:Over the two time periods, emergency asthma care in pregnant women has significantly improved. However, with one in three pregnant women being discharged home without systemic corticosteroids, further improvement is warranted.
Background: A multicenter study in the late 1990s demonstrated suboptimal emergency asthma care for pregnant women in US emergency departments (EDs). After a decade, follow-up data are lacking. We aimed to examine changes in emergency asthma care of pregnant women since the 1990s.
Methods: We combined data from four multicenter observational studies of ED patients with acute asthma performed in 1996-2001 (three studies), and 2011-2012 (one study). We restricted the data so that comparisons were based on the same 48 EDs in both time periods. We identified all pregnant patients aged 18 to 44 years with acute asthma. Primary outcomes were treatment with systemic corticosteroids in the ED, and, among those sent home, at ED discharge.
Results: Of 4895 ED patients with acute asthma, the analytic cohort comprised 125 pregnant women. Over the two time periods, there were no significant changes in patient demographics, chronic asthma severity, or initial peak expiratory flow. In contrast, ED systemic corticosteroids treatment increased significantly from 51% to 78% across the time periods (OR 3.11; 95%CI 1.27-7.60; P=0.01); systemic corticosteroids at discharge increased from 42% to 63% (OR 2.49; 95%CI 0.97-6.37; P=0.054). In the adjusted analyses, pregnant women in recent years were more likely to receive systemic corticosteroids, both in ED (OR 4.76; 95%CI 1.63-13.9; P=0.004) and at discharge (OR 3.18; 95%CI 1.05-9.61; P=0.04).
Conclusions: Over the two time periods, emergency asthma care in pregnant women has significantly improved. However, with one in three pregnant women being discharged home without systemic corticosteroids, further improvement is warranted.

PMID: 25358070 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Inconsistent Achievement Of Guidelines For Acute Asthma Care In Hospital EDs – Counsel & Heal


Counsel & Heal

Inconsistent Achievement Of Guidelines For Acute Asthma Care In Hospital EDs
Counsel & Heal
A new study compared the care delivered to patients coming to hospital emergency departments (EDs) for acute asthma attacks in recent years with data gathered more than 15 years earlier and found existing inconsistencies in how well hospitals are

View full post on asthma – Google News

Study finds inconsistent achievement of guidelines for acute asthma care in … – Medical Xpress

Study finds inconsistent achievement of guidelines for acute asthma care in
Medical Xpress
A study comparing the care delivered to patients coming to hospital emergency departments (EDs) for acute asthma attacks in recent years with data gathered more than 15 years earlier finds inconsistencies in how well hospitals are meeting nationally …

and more »

View full post on asthma – Google News

Study finds inconsistent achievement of guidelines for acute asthma care in … – EurekAlert (press release)

Study finds inconsistent achievement of guidelines for acute asthma care in
EurekAlert (press release)
A study comparing the care delivered to patients coming to hospital emergency departments (EDs) for acute asthma attacks in recent years with data gathered more than 15 years earlier finds inconsistencies in how well hospitals are meeting nationally …

and more »

View full post on asthma – Google News

Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease.

Related Articles

Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease.

Cochrane Database Syst Rev. 2014 Aug 2;8:CD003733

Authors: Knight-Madden JM, Hambleton IR

Abstract
BACKGROUND: Bronchodilators are used to treat bronchial hyper-responsiveness in asthma. Bronchial hyper-responsiveness may be a component of acute chest syndrome in people with sickle cell disease. Therefore, bronchodilators may be useful in the treatment of acute chest syndrome.
OBJECTIVES: To assess the benefits and risks associated with the use of bronchodilators in people with acute chest syndrome.
SEARCH METHODS: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings. Additional searches were carried out on MEDLINE (1966 to 2002) and Embase (1981 to 2002).Date of the most recent search of the Group’s Haemoglobinopathies Trials Register: 17 March 2014.
SELECTION CRITERIA: Randomised or quasi-randomised controlled trials. Trials using quasi-randomisation methods will be included in future updates of this review if there is sufficient evidence that the treatment and control groups are similar at baseline.
DATA COLLECTION AND ANALYSIS: We found no trials investigating the use of bronchodilators for acute chest syndrome in people with sickle cell disease.
MAIN RESULTS: We found no trials investigating the use of bronchodilators for acute chest syndrome in people with sickle cell disease.
AUTHORS’ CONCLUSIONS: If bronchial hyper-responsiveness is an important component of some episodes of acute chest syndrome in people with sickle cell disease, the use of inhaled bronchodilators may be indicated. There is need for a well-designed, adequately-powered randomised controlled trial to assess the benefits and risks of the addition of inhaled bronchodilators to established therapies for acute chest syndrome in people with sickle cell disease.

PMID: 25086371 [PubMed – as supplied by publisher]

View full post on pubmed: asthma